Aclaris Therapeutics, Inc. ACRS
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About ACRS
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Aclaris Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing immuno-inflammatory therapies and specialty dermatology treatments. The company operates primarily in the biotechnology and pharmaceutical industries, with an emphasis on small-molecule and kinase inhibitor therapies targeting immune-mediated diseases. Historically, Aclaris generated revenue from commercial dermatology products, but in recent years it has shifted toward a development-stage biotechnology model centered on immunology and inflammation-focused drug candidates.
The company’s primary business lines include research and development of oral and topical therapeutics, particularly kinase inhibitors targeting pathways associated with inflammatory and autoimmune conditions. Aclaris has pursued indications in dermatology, rheumatology, and immunology, including alopecia areata and atopic dermatitis. The company was founded in 2012 and expanded initially through acquisitions and commercialization of dermatology products before restructuring its portfolio to prioritize pipeline development and strategic partnerships. Its positioning has been supported by internal drug discovery capabilities and expertise in kinase biology.
Business Operations
Aclaris conducts operations primarily through its research and development organization, with activities concentrated in drug discovery, preclinical research, and clinical-stage development programs. The company’s core assets have included selective kinase inhibitor platforms and immuno-inflammatory compounds. Revenue historically came from marketed dermatology therapies and licensing arrangements, although more recent financial filings indicate the company is primarily supported through cash reserves, collaborations, and strategic transactions tied to pipeline assets.
Operations are centered in the United States, with research activities supported through internal scientific teams and external contract research organizations. Aclaris has entered into partnerships and licensing agreements involving development-stage compounds and intellectual property. The company has also maintained proprietary research capabilities related to kinase inhibitor chemistry and immunological disease mechanisms. Public filings identify collaborations and strategic relationships tied to development and commercialization opportunities, though some pipeline programs have been discontinued or deprioritized following portfolio reviews and restructuring efforts.
Strategic Position & Investments
Aclaris has strategically repositioned itself toward becoming a focused immunology and inflammation biotechnology company. Management has emphasized capital preservation, prioritization of high-value clinical assets, and advancement of selective kinase inhibitor programs. Growth initiatives have included clinical development of investigational therapies targeting inflammatory pathways and evaluation of partnering opportunities for non-core assets. The company has also implemented operational restructuring measures intended to extend cash runway and concentrate resources on key pipeline candidates.
Historically, Aclaris expanded through acquisitions of dermatology-related assets and commercial products, including the acquisition of Confluence Life Sciences to strengthen its drug discovery capabilities. The company has invested in proprietary technologies associated with kinase inhibition and immune pathway modulation. Its strategic direction reflects broader industry interest in targeted immunotherapies and precision inflammatory disease treatments. Public disclosures indicate ongoing evaluation of business development opportunities, although certain development programs have experienced delays, discontinuations, or strategic reassessments based on clinical and financial considerations.
Geographic Footprint
Aclaris Therapeutics is headquartered in Wayne, Pennsylvania, and its principal operations are concentrated in the United States. The company’s clinical development activities have included engagement with trial sites and research partners across multiple regions, though its primary operational infrastructure remains domestic. Its regulatory and investor communications are filed through the U.S. public markets as a Nasdaq-listed company under the ticker ACRS.
While Aclaris does not maintain the same global commercial footprint as large multinational pharmaceutical companies, it has pursued international intellectual property protections and development opportunities through partnerships and licensing structures. Clinical programs and research collaborations have involved stakeholders in North America and other international markets depending on trial requirements and strategic initiatives. Publicly available information indicates that the company’s direct commercial operations outside the United States are limited.
Leadership & Governance
Aclaris Therapeutics is led by an executive team with backgrounds in biotechnology, pharmaceutical development, immunology, and capital markets. The company’s leadership strategy has focused on advancing targeted immuno-inflammatory therapies while maintaining disciplined allocation of capital and prioritizing pipeline assets with differentiated scientific profiles. Governance oversight is provided through its board of directors and executive leadership structure consistent with U.S. public biotechnology company standards.
Key executives identified in recent public filings include:
- Neal Walker, M.D. – Executive Chair
- Dr. Frank Ruffo – Chief Executive Officer
- Christopher James – Chief Financial Officer
- Joseph Monahan, Ph.D. – Chief Scientific Officer
- Mary Szela – Board Member and biotechnology executive
The company’s leadership philosophy has emphasized scientific rigor, focused clinical development, and strategic portfolio management designed to balance innovation with financial sustainability.